home > news > detailed info

Quanticate Partners with CluePoints to Offer Data Quality Oversight capabilities

Quanticate’s new service enables centralised statistical monitoring in response to the amendments to the ICH Good Clinical Practice (GCP) E6(R2) guidelines.

By partnering with CluePoints, Quanticate will offer customers the creation of statistical analytics reports on key risk indicators and comprehensive risk signals across all clinical and operational data which enable sponsors to interpret findings to assess the integrity of their trial sites and associated data.

These reports allow for corrective and preventive measures to be taken that ensure the highest data quality and avoid errors that may otherwise may have gone undetected until submission review by the regulatory bodies.

Karen Ooms, EVP and head of statistics at Quanticate said: “Data quality oversight is a key component of risk-based monitoring (RBM) and ensures that data is submission ready. When a biometrics CRO like Quanticate does not conduct the monitoring it can focus on quality oversight of site data and then provide guidance to sponsors.

“The CluePoints tool performs statistical tests and provides visualisations for users to quickly identify outliers and various atypical data patterns indicative of operational risk, and enables Quanticate Statistical Consultants to provide guidance and recommendations so that a sponsors trial can take on a Risk based approach.

“CluePoints have established themselves in the market with endorsement from the FDA and the fact that centralized statistical monitoring can be performed across all investigative site data, not just subject data is highly valuable.

“Selecting CluePoints is just the first step of a larger solution we are developing and looking to provide for any pharmaceutical, biotechnology or medical device company that do not currently have centralised statistical monitoring capabilities in-house to support data quality integrity for submission and RBM erroneous data identification, or those that do but require a more sophisticated statistical approach to their existing monitoring plans.”

Dr Daniel Chapple, director at Quanticate added: “By partnering with CluePoints we have the tools to provide statistical insights into a trial to improve data quality on an ongoing basis and to support a RBM approach which has grown in popularity due to the ICH GCP E6(R2).

“The importance of high quality statistics is the foundation that Quanticate is built on and having industry leading tools in place together with expert statisticians puts us in an ideal place to provide high quality, independent statistical oversight to avoid surprises at submission.

“Centralised statistical monitoring is not just a feature of full service clinical monitoring CROs, as data experts such as ourselves, we can offer guidance and statistical advice that is independent to a full service CRO.

“The CluePoints tool enables Quanticate’s statistical consultants the ability to quickly discover potential outliers and erroneous data rather than waiting for issues to be identified during the submission process which can cause long and costly delays to pharmaceutical companies.”

Patrick Hughes, chief commercial officer at CluePoints reinforced the value of the relationship: “Over the last 5 years CluePoints has seen a growing demand for central statistical monitoring and data quality oversight to create greater cost and resource efficiencies within clinical trials. Quanticate’s deep domain expertise in statistics and data management coupled with a comprehensive and rigorous suite of risk-detection algorithms from CluePoints gives biopharma sponsors the ideal combination of software and service to improve data quality and integrity whilst complying with regulatory requirements. In the future we anticipate that this approach will be used in every trial to effectively reduce risk and improve quality.”

About CluePoints
CluePoints® is a Risk-Based Monitoring and Central Statistical Monitoring solution that has been designed and perfected over the last 10 years. It employs unique statistical algorithms to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA and EMA, CluePoints® is deployed to support traditional on-site monitoring and to drive a Risk-Based Monitoring strategy. The value of using CluePoints® lies in its powerful and timely ability to identify anomalous data and site errors allowing improvement in clinical data quality, optimization of on-site monitoring and a significant reduction in overall regulatory submission risk.

About Quanticate
Quanticate is a global data focused clinical research organisation (CRO) primarily focused on the management, analysis and reporting of data from clinical trials and post-marketing surveillance. Quanticate provides high quality teams that offer efficient outsourcing solutions for clinical data management, biostatistics, SAS programming, centralised statistical monitoring, medical writing and pharmacovigilance. Quanticate can offer study level support, functional service provision (FSP), strategic full data-services solutions or technical consultancy to meet the needs of pharmaceutical, biotechnology and device companies across the globe.
Visit for further information.

Media contact
For further information, images and interview opportunities, please contact Matt Dent at ramarketing: | +44 (0)191 222 1242 | |Twitter:@ramarketingpr | Facebook: /ramarketingpr | LinkedIn: /ramarketing
Print this page
Send to a friend
News and Press Releases

PHARM Connect 2019

Life science and business are going to meet at PHARM Connect on the 12-13 of March 2019 in Budapest, Hungary to continue the tradition of providing high calibre, customised professional partnering opportunities for pharma and biotech professionals from Central & Eastern European and beyond and deliver the crucial information they need to excel in their work. The influential annual gathering brings together over 400 global and regional decision-makers, top scientists, industry executives and business development leaders for the ninth time to identify new business opportunities, technologies, state-of-the-art formulation development strategies and to foster exchange of ideas on the role of the sector.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

Industry Events

Bio Europe Spring 2019

25-27 March 2019, Messe Wien Exhibition and Congress Center, Vienna

BIO-Europe Spring® is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe®, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative startups.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement